Skip to main content

Table 1 Summary of the results

From: RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis

  Diagnosis Perifascicular atrophya Perifascicular atrophy (2 rows) RIG-I+ Total
Inflammatory myopathy (n = 71) DM 16 (36%) 11 (25%) 22 (50%) 44
PM 0 (0%) 0 (0%) 0 (0%) 16
IBM 0 (0%) 0 (0%) 2 (33%) 6
IMNM 0 (0%) 0 (0%) 0 (0%) 5
Overlapped myopathy (n = 26) ASSb 7 (88%) 1 (13%) 1 (13%) 8
RA 0 (0%) 0 (0%) 1 (50%) 2
SLE 1 (50%) 1 (50%) 1 (50%) 2
SSc 3 (60%) 2 (40%) 1 (20%) 5
Sjögren 1 (20%) 0 (0%) 0 (0%) 5
MCTD 1 (25%) 1 (25%) 1 (25%) 4
Muscle dystrophy (n = 8) Dysf 0 (0%) 0 (0%) 0 (0%) 4
FSHD 0 (0%) 0 (0%) 0 (0%) 4
Total 29 (28%) 16 (15%) 29 (28%) 105
  1. Healthy controls were excluded from this analysis. DM dermatomyositis, PM polymyositis, IBM inclusion body myositis, IMNM immune-mediated necrotizing myopathy, ASS anti-synthetase syndrome, RA rheumatoid arthritis, SLE systemic lupus erythematosus, SSc scleroderma and scleromyositis, MCTD mixed connective tissue disease, Dysf dysferlinopathy, FSHD fascioscapulohumeral muscle dystrophy. aPerifasicular atrophy includes one or more rows of atrophic muscle fibers. bThe group of ASS patients was established by the presence of anti-Jo-1 antibodies